Tocilizumab-induced immunocomplex glomerulonephritis : a report of two cases

• Material Type: 記事
• Title: Tocilizumab-induced immunocomplex glomerulonephritis : a report of two cases
• Author/Editor: Daichi Fukaya; Tsutomu Inoue; Yuta Kogure
• Publication, Distribution, etc.: 日本 : Springer Nature
• Publication Date: 2020-04-27
• Publication Date (W3CDTF): 2020-04-27
• Periodical title: CEN case reports
• No. or year of volume/issue: 9(4)
• Volume: 9(4)
• ISSN (Periodical Title): 2192-4449
• Text Language Code: eng
• DOI: 10.1007/s13730-020-00478-6; https://doi.org/10.1007/s13730-020-00478-6
• Persistent ID (NDL): info:ndljp/pid/11675024; https://dl.ndl.go.jp/pid/11675024
• Collection: 障害者向け資料
• Collection (Materials For Handicapped People:1): テキストデータ
• Collection (particular): 国立国会図書館デジタルコレクション > 電子書籍・電子雑誌 > その他; https://dl.ndl.go.jp/collections/B00035
• Acquisition Basis: オンライン資料収集制度
• Date Accepted (W3CDTF): 2021-05-28T18:00:25+09:00
• Date Captured (W3CDTF): 2021-05-11
• Format (IMT): application/pdf
• Access Restrictions: 国立国会図書館内限定公開
• Service for the Digitized Contents Transmission Service: 図書館・個人送信対象外
• Availability of remote photoduplication service: 可
• Periodical Title (URI): https://link.springer.com/article/10.1007/s13730-020-00478-6
• Periodical Title (Persistent ID (NDL)): info:ndljp/pid/11675019; https://dl.ndl.go.jp/pid/11675019
• Data Provider (Database): 国立国会図書館 : 国立国会図書館デジタルコレクション; https://dl.ndl.go.jp

• Summary, etc.: コレクション : 国立国会図書館デジタルコレクション > 電子書籍・電子雑誌 > その他
• DOI: 10.1007/s13730-020-00478-6; https://doi.org/10.1007/s13730-020-00478-6
• Related Material (URI): http://id.ndl.go.jp/digimeta/11675024; https://dl.ndl.go.jp/pid/11675024; https://link.springer.com/content/pdf/10.1007/s13730-020-00478-6.pdf; https://link.springer.com/article/10.1007/s13730-020-00478-6/fulltext.html; https://search.jamas.or.jp/link/ui/2021219917
• References: Tocilizumab for focal segmental glomerulosclerosis secondary to multicentric Castleman’s disease; https://cir.nii.ac.jp/crid/1360285706177371520; TAFRO syndrome successfully treated with tocilizumab: A case report and systematic review; https://cir.nii.ac.jp/crid/1360292621601031680; Short-term add-on tocilizumab and intravenous cyclophosphamide exhibited a remission-inducing effect in a patient with systemic lupus erythematosus with refractory multiorgan involvements including massive pericarditis and glomerulonephritis; https://cir.nii.ac.jp/crid/1360574093578017920; Tocilizumab-induced immune complex glomerulonephritis in a patient with rheumatoid arthritis; https://cir.nii.ac.jp/crid/1360848659686142336; Autoimmune Diseases Induced by TNF-Targeted Therapies; https://cir.nii.ac.jp/crid/1360855568973828608; Tocilizumab improves systemic rheumatoid vasculitis with necrotizing crescentic glomerulonephritis; https://cir.nii.ac.jp/crid/1360855569646597248; Low immunogenicity of tocilizumab in patients with rheumatoid arthritis; https://cir.nii.ac.jp/crid/1360855570713858816; A benefit and the prospects of IL-6 inhibitors in idiopathic multicentric Castleman's disease; https://cir.nii.ac.jp/crid/1361418519096588672; Tocilizumab reduces complement C3 and C4 serum levels in rheumatoid arthritis patients; https://cir.nii.ac.jp/crid/1361699995160090368; Tocilizumab Promotes Regulatory T-cell Alleviation in STAT3 Gain-of-function−associated Multi-organ Autoimmune Syndrome; https://cir.nii.ac.jp/crid/1361981470108425984; Complete remission of myeloperoxidase-anti-neutrophil cytoplasmic antibody-associated crescentic glomerulonephritis complicated with rheumatoid arthritis using a humanized anti-interleukin 6 receptor antibody; https://cir.nii.ac.jp/crid/1362262944783626624; Biologics-induced autoimmune renal disorders in chronic inflammatory rheumatic diseases: Systematic literature review and analysis of a monocentric cohort; https://cir.nii.ac.jp/crid/1362262946066462720; Peripheral blood CD4+CD25+CD127low regulatory T cells are significantly increased by tocilizumab treatment in patients with rheumatoid arthritis: increase in regulatory T cells correlates with clinical response; https://cir.nii.ac.jp/crid/1362544420345040896; Immunogenicity of tocilizumab in patients with rheumatoid arthritis; https://cir.nii.ac.jp/crid/1363107370596853888; Tocilizumab: A Review in Rheumatoid Arthritis; https://cir.nii.ac.jp/crid/1363951793656135808; IL-6 Regulates In Vivo Dendritic Cell Differentiation through STAT3 Activation; https://cir.nii.ac.jp/crid/1364233268277869824; New-onset cutaneous sarcoidosis under tocilizumab treatment for giant cell arteritis: a quasi-paradoxical adverse drug reaction. Case report and literature review; https://cir.nii.ac.jp/crid/1364233269742441344; Successful Treatment of a Mesangial Proliferative Glomerulonephritis with Interstitial Nephritis Associated with Castleman's Disease by an Anti-interleukin-6 Receptor Antibody (Tocilizumab); https://cir.nii.ac.jp/crid/1390282679850005888; https://cir.nii.ac.jp/crid/1880583642701033216; Efficacy of tocilizumab, a humanized neutralizing antibody against interleukin-6 receptor, in progressive renal injury associated with Castleman’s disease; https://cir.nii.ac.jp/crid/2051996266978741248
• Data Provider (Database): 国立情報学研究所 : CiNii Research; https://cir.nii.ac.jp/
• Original Data Provider (Database): 雑誌記事索引データベース; https://ndlsearch.ndl.go.jp; Crossref; https://www.crossref.org; 科学研究費助成事業データベース; https://kaken.nii.ac.jp/ja
• Bibliographic ID (NDL): 11675024; http://id.ndl.go.jp/bib/11675024